Please login to the form below

Not currently logged in
Email:
Password:

Alder Biopharmaceuticals

This page shows the latest Alder Biopharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Novartis says migraine prevention drug clears phase III trial

Novartis says migraine prevention drug clears phase III trial

Novartis and Amgen are in a race withand Alder Biopharmaceuticals to bring the first CGRP-blocking drug to market.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics